Okay - I read the transcripts and it says this medication is for a small patient group. There are 400,000 patient with Parkinson's and half of them have delusions. That seems like a pretty small market. Even if this thing is flying off of the shelves, what kind of evaluation are we looking at? Anyone care to venture?